Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

20152,025 citationsJournal Articlebronze Open Access

Authors

Martin Schlumberger · Institut Gustave Roussy

Makoto Tahara · National Cancer Center Hospital East

Lori J. Wirth · Massachusetts General Hospital

Bruce Robinson · University of Sydney

Marcia S. Brose · University of Pennsylvania

Rossella Elisei · University of Pisa

Mouhammed Amir Habra

Abstract

Lenvatinib, as compared with placebo, was associated with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer. Patients who received lenvatinib had more adverse effects. (Funded by Eisai; SELECT ClinicalTrials.gov number, NCT01321554.).

Topics & Keywords

Thyroid Cancer Diagnosis and Treatment Radiomics and Machine Learning in Medical Imaging Radiation Dose and Imaging

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 7, pp. 621-630

DOI: 10.1056/nejmoa1406470

Field-Weighted Citation Impact: 118.36